First-Line Treatment for EGFR-mutated Advanced/Metastatic Non-Small-Cell Lung Cancer: A 55-Year-Old Man

An expert discusses the case of a 55-year-old man with EGFR-mutated advanced/metastatic NSCLC, focusing on treatment considerations and management strategies.

An expert discusses recent updates on first-line treatments in EGFR-mutated NSCLC, including the MARIPOSA trial comparing amivantamab + lazertinib vs osimertinib, and the FLAURA2 trial of osimertinib + chemotherapy, and how the data is likely to impact the treatment landscape.

An expert discusses treatment goals for patients with EGFR-mutated advanced/metastatic NSCLC, how to approach combination therapy with high-risk patients, and how recent data has influenced their practice.

An expert discusses a treatment approach for the patient case above, how factors like brain metastases influence first-line treatment choices, reviews high-risk/CNS outcomes data from MARIPOSA and FLAURA2, and shares their impression of icPFS and DoR from MARIPOSA, along with how to determine which patients are best suited for either combination treatment option.

An expert discusses the safety profiles of combination regimens, effective strategies for managing side effects, and how to weigh the potential for toxicity versus efficacy/benefits when discussing treatment options with patients.

An expert shares clinical pearls with the community, offering insights and tips for managing patients effectively.